The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

What did we REALLY learn from the NordICC colonoscopy study?

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Earlier this week, The New England Journal of Medicine published the first results of the Pragmatic Nordic-European Initiative on Colorectal Cancer (NordICC) Trial of Colonoscopy, which was conducted in Poland, Norway, Sweden, and the Netherlands to measure the efficacy of colonoscopy in reducing colorectal cancer incidence and mortality. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
William L. Dahut, MD
Chief scientific officer, American Cancer Society
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

UF Health Cancer Center rolls out mobile cancer screening vehicle

UF Health officials and supporters gathered Wednesday to unveil the UF Health Cancer Center’s Mobile Cancer Screening Connector, which will take cancer screening care to a 23-county area in North Florida. UF Health photo by Nate GuidryThe University of Florida Health Cancer Center launched a 40-foot-long mobile cancer screening bus that will expand access to cancer screenings and essential health care services, including 3D mammograms and cervical, colon, and prostate cancer screenings.
Byline
William L. Dahut, MD
Chief scientific officer, American Cancer Society
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account